## Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones.

Filippo Dragoni, Abena K. Kwaa, Caroline C. Traut, Rebecca T. Veenhuis, Bezawit A. Woldemeskel, Angelica Camilo-Contreras, Haley E. Raymond, Arbor G. Dykema, Eileen P. Scully, Amanda M. Rosecrans, Kellie N. Smith, Frederic D. Bushman, Francesco R. Simonetti, and Joel N. Blankson.

#### **Supplementary Materials**

#### Table of contents

### **Supplementary Figures**

-Figure S1. Epigenetic signatures surrounding the proviruses of interest.

-Figure S2. Outgrowth ex vivo of ZNF470i and ZNF721i.

-Figure S3. Proliferation of HIV-1-infected cells upon stimulation with selected Gag peptides.

-Figure S4. Cells carrying ZNF470i are not reactive to Gag peptides.

**-Figure S5.** Analysis of U5-gag sequence from culture supernatant, related to Figures 4 and 5. **-Figure S6.** Intracellular cytokine staining of CD8<sup>+</sup> T cells stimulated with Gag peptides 41, 42, and 61.

**-Figure S7**. Quantification of the CASSLTGGGEQFF clonotype by duplex VDJ-specific ddPCR and analysis of provirus-TCR co-occurrence.

-Figure S8. Gag protein sequence analysis of proviruses of interest.

-Figure S9. Nef protein sequence analysis of proviruses of interest.

#### **Supplementary Tables**

**-Table S1.** Characteristics of previously published proviruses integrated into *ZNF721/ABCA11P*.

-Table S2. Oligos used in this study.

Chromosome 19 (hg19)



415000 418000 421000 424000 427000 430000 430000 43000 43000 44000 44000 44000 451000 454000 457000 46000 46000 46000 46000 46000 47000 47000 47000 484000 487000 48000 49000 49000 49000 49000 50200 505000 508000 511000



B



# Chromosome 7 (hg19)

53710000 53750000 53790000 53830000 53870000 53910000 53950000 54930000 54030000 54070000 54150000 54190000 54230000 54230000 54350000 54350000 54390000 54430000 54550000 54550000 54550000 54550000 54550000 54630000 54670000 54710000 54750000

FLJ45974
FLJ45974
VSTM2A
VSTM2A
Polycomb repressed
Polycomb repressed<



**Supplemental Figure S1. Epigenetic signatures surrounding the proviruses of interest.** CHIP-seq data from CD4<sup>+</sup> T cells available through the ROADMAP Epigenomics Program database were visualized with Epigenome broswer and Epilogos (see methods); gene tracks show genes surrounding the proviruses of interest: ZNF470i (A), ZNF721i (B), and Chr7.d11sc (C); Epilogos were generated based on seven datasets from primary CD4<sup>+</sup> T cells (E037, E038, E039, E040, E041, E042, E043); histone modification tracks from a representative sample (E043 Primary T helper cells from peripheral blood) are displayed below the Epilogos track.



Supplemental Figure S2. Additional reservoir characterization of CD4<sup>+</sup> T cells post chemoradiation. (A) Schematic of experimental design; CD4<sup>+</sup> T cells were isolated from PBMCs collected from day 1400 post CRT; cells were used for quantitative viral outgrowth assay seeding 20 wells with 200,000 cells each; the remaining cells were used for the quantification of proviruses from gDNA, and isolation of cell-associated RNA from aliquots at limiting dilution for HIV-1 RNA positive cells; aliquots were screened for U5-PBS RNA and used as input for single genome sequencing; cells assayed in each method are indicated in grey. (B) Frequency of proviruses of interest measured by dPCR assays targeting the human-LTR junction; each symbol represents a replicate; error bars indicate mean and standard deviation; mean values are indicated in black; grey symbols indicate negative values. (C) Infectious units per million estimated from the qVOA; p24<sup>+</sup> wells were sequenced, and IUPM were calculated for each variant matching proviruses of interest as in D; error bars indicate the 95% confidence intervals. (D) U5-gag maximum likelihood tree showing variants recovered from qVOA and cell-associated RNA, together with reference sequences of proviruses of interest. (E) Estimate of inducibility in vitro calculated by dividing the number of qVOA wells positive for a specific variant by the total number of its corresponding proviruses seeded in the qVOA experiment (based on their frequency as in B).



Supplemental Figure S3. Proliferation of HIV-1-infected cells upon stimulation with selected Gag peptides. (A) Schematic of experimental design; overlapping Gag peptides were selected based on response to elispot assay. (B) CD8-depleted PBMCs were stimulated in presence of individual peptides for 9 days; genomic DNA from total cells was used to quantify total HIV-1 LTR copies; no Tx indicate cells left untreated; NTC indicates water dPCR water control; dashed line indicates baseline HIV-1 DNA level in unstimulated cells; statistical significance was tested by one-way ANOVA; \* p<0.05, \*\* p<0.01, \*\*\* p<0.001 \*\*\*\* p<0.001. (C) Results expressed as fold-change relative to no treatment.



**Supplemental Figure S4. Cells carrying ZNF470i are not reactive to Gag peptides.** (A) CD8-depleted PBMCs were cultured for 9 days without treatment (no Tx) or upon addition of mini-pools of Gag peptides, each containing 10-11 overlapping peptides; genomic DNA was extracted from total cells at the end of culture to quantify copies of proviruses of interest harnessing the site of HIV-1 integration; each circle represents a dPCR technical replicate; grey circles indicate values below the limit of detection. Mini-pool number 6 is circled to indicate it led to a significant increase in ZNF721i copies.



**Supplemental Figure S5. Analysis of U5-gag sequence from culture supernatant, related to Figures 4 and 5.** (A) Schematic of the sequencing approach to profile HIV-1 variants produced in response to CD8-depleted PBMC stimulation with peptide 61; the gray shaded area indicated the amplicon spanning between the 5'-leader and gag, which contains the two mutations that distinguish ZNF470i from ZNF721i. (B) Distribution of variants of interest in two control samples without treatment (No Tx) and in 5 smaples treated with peptide 61. (C) Cumulative data from all 5 samples stimulated with peptide 61.



Supplemental Figure S6. Intracellular cytokine staining of CD8<sup>+</sup> T cells stimulated with Gag peptides 41, 42, and 61. (A) Intracellular cytokine staining of CD8<sup>+</sup> T cells re-stimulated with Gag peptides of interest after PBMC expansion; numbers within gates indicate the percentage of cells positive for both TNF $\alpha$  and IFN $\gamma$ .





VD junction HEX



, and the second second

Supplemental Figure S7. Quantification of the CASSLTGGGEQFF clonotype by duplex VDJ-specific ddPCR and analysis of provirus-TCR co-occurrence. (A) Design of duplex strategy to specifically amplify the VDJ rearrangement of the CASSLTGGGEQFF CDR3β; probes were designed to anneal across the VDJ junction to exploit V, D, and J chain diversity, as well as junctional diversity (N1 and N2 nucleotides). (B) Representative 2D plots of droplet digital PCR reactions with water negative control, whole genome amplified DNA not containing the ZNF721i provirus, and DNA from CD4<sup>+</sup> T cells cultured for 10 days with no treatment, or stimulation with the cognate Gag peptide 61. (C) Co-occurrence analysis and conbinatorial statistics to determine whether ZNF721i and CASSLTGGGEQFF belong to the same cell clonotype.



**Supplemental Figure S8. Gag protein sequence analysis of proviruses of interest.** (A) Gag protein sequences were codon aligned to the HXB2 reference; black boxes indicate targeted epitopes; red lines indicate HLA-B\*57–restricted epitopes; numbers next to QVOA sequences indicate days from the start of chemoradiation.

Α	10	20	30	40	50	60	70	80 90
HXB2-LAI	MGGKWSKSSVI	GWPTVRERMRRA	EPAADRVGAASRI	LEKHGAITS	SNTAATNAACAV	LEAQEEEEV	GFPVTPQVPLR	PMTYKAAVDLSHF
QVOA -2224			G	L	<b>T</b> N <b>D</b>	к.	RI	<b>L</b>
QVOA 151	LV		G	L	<b>T</b> N <b>D</b>	ĸ.	RI	<b>L</b>
QVOA 490	LV	••••••	G	L	<b>T</b> N <b>D</b>	ĸ	RI	· · · · · · · <b>L</b> · · · · ·
	LV		G	······································		K.	RI	· · · · · · · · · · · · · · · · · · ·
ZNF/211 Chr7 d11co		•••••••••	G	т.	T D	ĸ	R	т. т
Chir.urisc								
HXB2-LAI QVOA -2224 QVOA 151 QVOA 490 ZNF470i ZNF721i Chr7.d11sc	100	110 HS QRQDILDIW. Y. K Y K Y K Y K Y K	120 IXHTQGYFPD*Qi V V V V V V V V V V V V V V V V V V V	130 	140 PLTFGWCYKLVE . Y . F. . Y . F. . Y . F. . Y . F. . Y . F.	150 	160 <b>NKGENTSLLHP</b> <b>E</b> . N <b>E</b> N <b>E</b> N <b>E</b> N <b>E</b> N <b>E</b> SN	170 180 
HXB2-LAI QVOA -2224 QVOA 151 QVOA 490 ZNF470i ZNF721i	190 	200 HHVARELHPEYFI .M.M.Y .M.M.Y .M.M.Y .M.Y	.   .D# - .D# - .D# - .D# - .D# -					

**Supplemental Figure S9. Nef protein sequence analysis of proviruses of interest.** (**A**) Nef protein sequences were codon aligned to the HXB2 reference; black boxes indicate targeted epitopes; grey box indicate overlapping epitope at positions 83-103; red lines indicate HLA-B\*57–restricted epitopes; numbers next to QVOA sequences indicate days from the start of chemoradiation.

.A.K....M...M...Y.D.\*

Chr7 d11sc

#### Supplemental Table S1. Characteristics of previously published proviruses integrated into ZNF721/ABCA11P.

Stu	dy	Provirus information					Participant characteristics										
Reference	Pubmed_id	Retrovirus Integration Database_id	Chromoso me	Insert position*	Provirus orientation	ZNF721 gene orientation	Assays used	Evidence of intactness	Evidence of inducibility	Participant id	Clinical notes	Age (years)	Sex	Race ethnicity	On ART	Years on ART	Plasma HIV RNA
This study			chr4	447418	÷	-	NFL proviral sequencing, LM-PCR/ISA, QVOA	Yes	induced by cognate antigen via PBMC stimulation	ES24	EC on ART	60	м	African American	yes	3	suppressed
Guo 2022, Halvas 2020	36044447	rid36044447_23888	chr4	443311	+	-	NFL proviral sequencing, LM-PCR/ISA, QVOA	Yes	inducible by QVOA, source of NSV	F07	NSV	59	м	African American	ves	19	NSV
Guo 2022	36044447	rid36044447_23886 rid36044447_23887 rid36044447_23890	chr4 chr4 chr4	439930 440816 446377	+ + +	-	LM-PCR/ISA		unknown	10		00		, undan , undan dan	,00		101
Guo 2022, Halvas 2020	36044447	rid36044447_35276	chr4	425766	+	-	NFL proviral sequencing, LM-PCR/ISA, QVOA	Yes	inducible by QVOA								
		rid36044447_35281 rid36044447_35282 rid36044447_35284 rid36044447_35286 rid36044447_35294	chr4 chr4 chr4 chr4 chr4	434674 441824 441923 462538 488671	- + + +	-				R09	NSV	73	М	Caucasian	yes	10	NSV
Guo 2022	36044447	rid36044447 10322 rid36044447_10323 rid36044447 10324 rid36044447_10328 rid36044447_10329 rid36044447_10330	chr4 chr4 chr4 chr4 chr4 chr4	425632 439826 443536 449724 465001 466440	+ + + + +	-	LM-PCR/ISA		unknown	C03	NSV	43	м	Caucasian	yes	9	NSV
Eiunkauf 2019	30688658	rid30688658_36	chr4	442619	+	-	MIP-seq	Yes	unknown	P1		59	м		yes	11.5	suppressed
Jiang 2020, Lian 2021	32848246		chr4	444791	+	-	MIP-seq	Yes	unknown	P9/EC9	EC						suppressed
Lian 2021, Sun 2023	34910552		chr4	448830	+	-	MIP-seq, PHEP-seq	Yes	unknown	27/P5		62	М		yes	14	suppressed
Huang 2021	34636876	rid34636876_9	chr4	450716	+	-	Q4PCR, MIP-seq	Yes	unknown	5203		59	М	Caucasian	yes	21	suppressed
Coffin 2019	31217357	rid31217357_2486	chr4	443254	+	-	LM-PCR/ISA			CH62-1	Fiebig IV/V				yes	3.7	suppressed
Coffin 2019	31217357	rid31217357_3040	chr4	457831	+	-	LM-PCR/ISA			CH68-5	Fiebig IV/V				yes	3.6	suppressed
Bale 2021	33832973	rid33832973_8584	chr4	449365	+	-	LM-PCR/ISA		unknown	ZA011_preA	MTCT	0.8	F		no	0	viremic
Bale 2021 Bale 2021	33832973 33832973	rid33832973_10090 rid33832973_10091	chr4 chr4	439658 440131	+	-	LM-PCR/ISA LM-PCR/ISA			ZA012_preA	MTCT	0.4	м		no	0	viremic

#### Supplemental Table S2. Oligonucleotides.

Primers and probes used for specific and total virus quantification									
Assay	Primer Name	PCR Reaction	Primer Type	Sequence (5'- 3')	Coordinates on HXB2	Reference			
	721_IS_Fw	Digital PCR	Forward	TGTACTTTCCAAGATACCAGAA					
ZNF721i Quantification	721_IS_Rev	Digital PCR	jital PCR Reverse GTAGCCTTGTGTGTGGTAGA		52-71	This work			
	721_IS_Probe	Digital PCR	Probe	5FAM/AGTATCTCT/ZEN/ATAGATACTGGAAGGGCT/3IABkFQ					
	470_IS_Fw	Digital PCR	Forward	5HEX/CTTATTTAT/ZEN/TAATTGGAAGGGCTAATTTACTC/3IABkFQ					
ZNF470i Quantification	470_IS_Rev	Digital PCR	Reverse	ATAACTTATCTGGGCTTTCCT	52-71	This work			
	470_IS_Probe	Digital PCR	Probe	GTAGCCTTGTGTGTGGTAGA					
	U5PBS_delvar_Fw	Digital PCR	Forward	CTAGAGATCCCTCAGACCCTTT	588-609				
Chr7 d11co compatition accov	U5PBS_delvar_Rev	Digital PCR	Reverse	ATTYGGCGTACTCACCAGTC	739-758	This work			
Chir.urise competition assay	delvar_PSP	Digital PCR	Probe	5HEX/CGAACAGGG/ZEN/ACTTGAAAACCAGAGGAGC/3IABkFQ	643-681	THIS WORK			
	U5PBS_probe	Digital PCR	Probe	5FAM/AAAGGGAAA/ZEN/CCAGAGGAGCTCTCTCGACAC/3IABkFQ	663-692				
	Chr7.d11sc_IS_Fw	Digital PCR	Forward	ATCTGAGACAAGGCTCAATCAA					
Chr7.d11sc Quantification	Chr7.d11sc_IS_Rev	Digital PCR	Reverse	GTTCTGCCAATCAGGGAAGTA	58-89	This work			
	Chr7.d11sc_IS_Probe	Digital PCR	Probe	5FAM/CAGGAGGTC/ZEN/CTAATTGGAAGGGCTAATT/3IABkFQ					
	RU5-F	Digital PCR	Forward	CTTAAGCCTCAATAAAGCTTGCC	517-539; 9601-9623	Andorson at al			
U5-R	RU5-R	Digital PCR	Reverse	GGATCTCTAGTTACCAGAGTC	577-597; 9661-9681	(20252074)			
	RU5-probe	Digital PCR	Probe	5FAM/AGTAGTGTG/ZEN/TGCCCGTCTG/3IABkFQ	552-570; 9636-9654	(30233074)			

Primers and probes used for specific TCR quantification									
Assay	Primer Name	PCR Reaction	Primer Type	Sequence (5'- 3')					
ZNF721i TCR Quantification	721TCR_Fw	Digital PCR	Forward	GCACACAGCAGGAGGAC					
	721TCR_Rev	Digital PCR	Reverse	GCTCACCCTCTCCCCA	This work				
	721TCR_Probe1	Digital PCR	Probe	5FAM/CCCGAAGAA/ZEN/CTGCTCACCGC/3IABkFQ	THIS WORK				
	721TCR_Probe2	Digital PCR	Probe	5HEX/ATCTCTGTG/ZEN/CCAGCAGCCTTACAGG/3IABkFQ					

Primers used for cDNA synthesis, single genome sequencing (SGS) and sanger sequencing									
Assay	Primer Name	PCR Reaction	Primer Type	Sequence (5'- 3')	Coordinates on HXB2	Reference			
cDNA synthesis/SGS	ES24_gag RO	outer	Reverse	TTAGCCTGTCTCTCAGTACAATC	2062-2084				
SGS/sanger sequencing	ES24_gag RN	nested/sanger	Reverse	TCATTTGGTGTCCTTCCTTTCC	2038-2059				
SGS	Delvar_4187_FO	outer	Forward	TGGGTACCAGCGCACAAAG	4152-4170	This work			
SGS/sanger sequencing	Delvar_4210_FN	nested/sanger	Forward	GAATTGGAGGAAATGAACAAGTAG	4171-4194	THIS WORK			
SGS	Delvar_5716_RO	outer	Reverse	TAGATATGTTGCCCTAAGCTATG	5676-5698				
SGS/sanger sequencing	Delvar_5687_RN	nested/sanger	Reverse	TAGCCTAGGAAAATGTCTAACAGC	5646-5669				
SGS	U5_gag_FO	outer	Forward	GTARCTAGAGATCCCTCAGAC	583-603				
SGS/sanger sequencing	U5_gag_FN	nested/sanger	Forward	AAATCTCTAGCAGTGGCGCC	621-640				
SGS	env_FO	outer	Forward	GCCAGTAGTRTCAACYGAA	6979-6997	Simonatti at al			
SGS/sanger sequencing	env_FN	nested/sanger	Forward	CTGCTAAATGGCAGTCTAGC	7001-7020	(22201425)			
SGS	env_RO	outer	Reverse	GCARATGAGTTTTCYAGAGCA	8015-8035	(55501425)			
SGS/sanger sequencing	env_RN	nested/sanger	Reverse	TTGCCTGGAGCTGYTTRATGC	7938-7958				
Sanger sequencing	INT3A2	sanger	Reverse	AGCTTCCTCATTGATGGTCTCTTT	1393-1416				
SGS	5CP1	outer	Forward	GAAGGGCACACAGCCAGAAATTGCAGGG	1981-2008				
SGS/sanger sequencing	2.5	nested/sanger	Forward	CCTAGGAAAAAGGGCTGTTGGAAATGTGG	2011-2039				
SGS	RT3.1	outer	Reverse	GCTCCTACTATGGGTTCTTTCTCTAACTGG	3830-3859				
SGS/sanger sequencing	RT3798R	nested/sanger	Reverse	CAAACTCCCACTCAGGAATCCA	3777-3798				
SGS	RT3597mixF	outer	Forward	AAAACAGGAAARTATGCAA	3597-3615				
SGS/sanger sequencing	RT3626F	nested/sanger	Forward	TGCCCACACTAATGATGTAA	3626-3645	Einkauf et al.			
SGS	SC05R	outer	Reverse	AGCTCTTCGTCGCTGTCTCCGCTT	5980-6003	(30688658)			
SGS/sanger sequencing	SC02R	nested/sanger	Reverse	CTTCCTGCCATAGGAGATGCCTA	5957-5979				
SGS	VP5450F	outer	Forward	CAGGACATAACAAGGTAGGATC	5450-5471				
SGS/sanger sequencing	VP5549F	nested/sanger	Forward	AGAGGATAGATGGAACAAGCCCCAG	5550-5574				
SGS	CO602	outer	Reverse	GCCCATAGTGCTTCCTGCTGCTCCCAAGAACC	7785-7816				
SGS/sanger sequencing	V3CR	nested/sanger	Reverse	TGCTCTTTTTTCTCTCTSCACCACT	7735-7759				

#### Primers used to confirm integration site

Assay	Primer Name	PCR Reaction	Primer Type	Sequence (5'- 3')	Coordinates on HXB2	Reference
	ZNF470_FO	outer	Forward	CAGTAGCGCTACTGTTTCTAATTC		
ZNE470i	ZNF470_FN	nested/sanger	Forward	CTACATATAACTTATCTGGGCTTTCC		This work
2111-4701	ZNF470_RO	outer	Reverse	GTTACCCAGGCTGGAGTTGAA		THIS WOLK
	ZNF470_RN	nested/sanger	Reverse	CACACCTGGCCCTACTTTCAGT		
	ZNF721_FO	outer	Forward	AATTTTATGTACTTTCCAAGATACCAG		
	ZNF721_FN	nested/sanger	Forward	TACCAGAAAAAAGTATCTCTATAGA		This work
ZNETZI	ZNF721_RO	outer	Reverse	TTTGTACTGATACACCTTTACTTCT		THIS WOLK
	ZNF721_RN	nested/sanger	Reverse	GGCGTATCTGCTAGAGATTTTC		
Chr7 d11cc	Delvar_FO	outer	Forward	CCATGCCTGTTAGAGAGTGTG		This work
Chir7.dilisc	Delvar_FN	nested/sanger	Forward	GAGACAAGGCTCAATCAATTTAG		THIS WORK
primers annealing to HIV	ES24_gag RO	outer	Reverse	TTAGCCTGTCTCTCAGTACAATC	2062-2084	
	ES24_gag RN	nested/sanger	Reverse	TCATTTGGTGTCCTTCCTTTCC	2038-2059	Simonetti et al.
	env_FO	outer	Forward	GCCAGTAGTRTCAACYGAA	6979-6997	(33301425)
	env_FN	nested/sanger	Forward	CTGCTAAATGGCAGTCTAGC	7001-7020	